Vertex Pharmaceuticals Incorporated (VRTX) Return on Equity (ROE): 22.41%
Is Vertex Pharmaceuticals Incorporated’s return on equity (ROE) high or low?
Vertex Pharmaceuticals Incorporated's return on equity (ROE) of 22.41% is 15% above its 5-year average of 19.47%, near the high end of its 5-year range (-3.26%–31.22%).
The return on equity (ROE) for Vertex Pharmaceuticals Incorporated (VRTX) is 22.41% as of Wednesday, June 10, 2026. It is above its 12-month average by 150.11% (8.96%).
VRTX Return on Equity (ROE) Chart
VRTX Average Return on Equity (ROE) Chart
VRTX Current vs Average Return on Equity (ROE) Chart
VRTX Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
22.41%
RETURN ON EQUITY (ROE) AVG TTM
8.96%
RETURN ON EQUITY (ROE) AVG 3Y
15.60%
RETURN ON EQUITY (ROE) AVG 5Y
19.47%
RETURN ON EQUITY (ROE) AVG 10Y
11.58%
RETURN ON EQUITY (ROE) AVG 15Y
-8.18%
RETURN ON EQUITY (ROE) AVG 20Y
-31.05%
CURRENT VS TTM AVG
+150.11%
CURRENT VS 3Y AVG
+43.68%
CURRENT VS 5Y AVG
+15.12%
CURRENT VS 10Y AVG
+93.58%
CURRENT VS 15Y AVG
+374.00%
CURRENT VS 20Y AVG
+172.17%
VRTX Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 22.41% | 8.96% | 15.60% | 19.47% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 36.25% | -8.30% | 7.76% | 4.45% |
| Medtronic plc (MDT) | $103.04B | 9.80% | 4.86% | 6.08% | 6.82% |
| CVS Health Corporation (CVS) | $125.16B | 3.79% | 4.23% | 6.35% | 7.74% |
| Danaher Corporation (DHR) | $130.25B | 6.97% | 7.38% | 9.51% | 10.24% |
| Elevance Health Inc. (ELV) | $87.43B | 11.94% | 13.69% | 14.71% | 14.93% |
| Cigna Corporation (CI) | $78.25B | 14.90% | 11.32% | 12.19% | 12.83% |
| Pfizer Inc. (PFE) | $146.36B | 8.31% | 9.04% | 13.32% | 16.07% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 17.05% | 15.07% | 13.91% | 13.46% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 39.19% | 20.05% | 21.63% | 19.46% |
Return Analysis
ROE
22.4%
ROA
16.4%
Vertex Pharmaceuticals Incorporated Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The return on equity (ROE) for VRTX stock is 22.41%.
- Is Vertex Pharmaceuticals Incorporated's return on equity (ROE) high or low?
- Vertex Pharmaceuticals Incorporated's return on equity (ROE) of 22.41% is 15% above its 5-year average of 19.47%, near the high end of its 5-year range (-3.26%–31.22%).
- What is the TTM average return on equity (ROE) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average return on equity (ROE) for VRTX stock is 8.96%.
- What is the 3Y average return on equity (ROE) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average return on equity (ROE) for VRTX stock is 15.60%.
- What is the 5Y average return on equity (ROE) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average return on equity (ROE) for VRTX stock is 19.47%.
- What is the 10Y average return on equity (ROE) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average return on equity (ROE) for VRTX stock is 11.58%.
- What is the 15Y average return on equity (ROE) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average return on equity (ROE) for VRTX stock is -8.18%.
- What is the 20Y average return on equity (ROE) for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average return on equity (ROE) for VRTX stock is -31.05%.
Vertex Pharmaceuticals Incorporated Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 21.18% |
| 2024-12-31 | -3.26% |
| 2023-12-31 | 20.59% |
| 2022-12-31 | 23.88% |
| 2021-12-31 | 23.19% |
| 2020-12-31 | 31.22% |
| 2019-12-31 | 19.34% |
| 2018-12-31 | 47.28% |
| 2017-12-31 | 12.99% |
| 2016-12-31 | -9.69% |
| 2015-12-31 | -59.38% |
| 2014-12-31 | -68.70% |
| 2013-12-31 | -32.81% |
| 2012-12-31 | -10.71% |
| 2011-12-31 | 3.76% |
| 2010-12-31 | -149.74% |
| 2009-12-31 | -58.52% |
| 2008-12-31 | -192.51% |
| 2007-12-31 | -144.23% |
| 2006-12-31 | -40.89% |
| 2005-12-31 | -85.05% |
| 2004-12-31 | -469.08% |
| 2003-12-31 | -102.03% |
| 2002-12-31 | -28.69% |
| 2001-12-31 | -13.93% |
| 2000-12-31 | -7.72% |
| 1999-12-31 | -19.60% |
| 1998-12-31 | -13.44% |
| 1997-12-31 | -7.17% |
| 1996-12-31 | -30.58% |
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani